DY

Daniel Yerace

Chief Operating Officer & General Counsel

Coeptis Therapeutics

Therapeutic Areas

Coeptis Therapeutics Pipeline

DrugIndicationPhase
COEP-001Relapsed/Refractory B-cell Malignancies (e.g., NHL, ALL)Phase 1
DARIC-NK ProgramHematologic MalignanciesPreclinical
SNAP-CAR Solid Tumor ProgramsSolid TumorsDiscovery/Preclinical